The 92 rating InvestorsObserver gives to Protalix Biotherapeutics Inc (PLX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, PLXs 92 overall rating means the stock scores better than 92 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Protalix Biotherapeutics Inc (PLX) stock is down -4.17% while the S&P 500 is higher by 0.06% as of 12:23 PM on Thursday, Feb 11. PLX is down -$0.24 from the previous closing price of $5.75 on volume of 700,795 shares. Over the past year the S&P 500 is up 15.77% while PLX is higher by 60.64%. PLX lost -$1.34 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Protalix Biotherapeutics Inc (PLX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

More:
Is Protalix Biotherapeutics Inc (PLX) the Top Pick in the Biotechnology Industry? - InvestorsObserver